Dr. Ranjit Deshmukh is a seasoned pharmaceutical executive with over 25 years of global experience spanning biologics, vaccines, monoclonal antibodies, ADCs, and advanced therapies such as cell and gene therapies. He has led end-to-end CMC and technical operations from early development to global commercialization, including over 10 product launches with many involving combination products and devices. Dr. Deshmukh has held leadership roles at Pfizer, AstraZeneca, Ocugen, and Immunovant, and currently serves as President at BiologixCMC. He has extensive expertise in tech transfer, process validation, regulatory strategy, and global internal and external manufacturing with CDMO/CRO partnerships. He has co-authored over 25 publications, delivered 50+ conference sessions/presentations, and contributed to QbD and ICH guideline implementation through ISPE, IFPAC and BPOG. Dr. Deshmukh holds a Ph.D. in Chemical Engineering.